## JNJ: Johnson & Johnson - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 -2.9% below STRENGTH zone (3.0-6.0%); PEG 1.07 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($193.90)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 7, Bearish: 0)

**1. Key facts: Johnson & Johnson Raises Dividend; Reports Positive Study Results**
- Source: TradingView | 20251209T200755 | Bullish | Relevance: 99%
-  Johnson & Johnson (JNJ) has increased its dividend for 63 consecutive years, offering a 2.58% yield with an annual payout of $5.20. The company also announced positive Phase 3 study results for TECVAYLI and DARZALEX FASPRO in treating relapsed multiple myeloma patients.

**2. If You Bought 10 Shares of Johnson & Johnson 10 Years Ago, You’d Have This Much Today**
- Source: GOBankingRates | 20251208T150918 | Bullish | Relevance: 99%
-  Investing in 10 shares of Johnson & Johnson (JNJ) stock 10 years ago, specifically on October 15, 2015, would have yielded a significant return. With the initial investment of $971.50, and by reinvesting all dividends, the total value of the holdings would be approximately $2,379 as of October 15, 2025. This represents a cumulative return of 144.9% over the decade, thanks to Johnson & Johnson's status as a "dividend king" with 63 consecutive years of increasing dividend payments.

**3. Ossiam Sells 506,439 Shares of Johnson & Johnson $JNJ**
- Source: MarketBeat | 20251208T120526 | Neutral | Relevance: 99%
-  Ossiam significantly reduced its stake in Johnson & Johnson ($JNJ) by selling 506,439 shares, decreasing its holdings by 79.4% in the second quarter. Despite this, other institutional investors have increased their positions. Johnson & Johnson's stock exhibits a "Moderate Buy" consensus rating with a target price of $203.15, and the company recently declared a quarterly dividend of $1.30 per share.

**4. ASH: J&J makes case for Tecvayli combo as an alternative to CAR-T in 2nd-line multiple myeloma**
- Source: Fierce Pharma | 20251209T120837 | Bullish | Relevance: 99%
-  Johnson & Johnson presented positive Phase 3 MajesTEC-3 trial data for its Tecvayli-Darzalex combination in multiple myeloma patients, showing an 83% reduction in progression or death risk. This regimen, which significantly improved overall survival, could be a strong alternative to CAR T-cell therapies like J&J’s own Carvykti, especially for patients who cannot access CAR-T in community settings. The data suggests potential competition for existing CAR-T treatments and highlights J&J's efforts to expand Tecvayli's role in earlier lines of therapy.

**5. Health changes everything: Europe’s smart investment**
- Source: Economist Impact | 20251209T090851 | Bullish | Relevance: 99%
- Europe faces demographic challenges including an aging population and rising chronic disease, which threaten economic growth. The article argues that treating healthcare as an investment rather than a cost can drive productivity, competitiveness, and prosperity, citing economic benefits that far outweigh the initial investment. It highlights how past austerity measures weakened health systems and calls for political decision-makers to prioritize long-term health outcomes and innovation.

### Analyst Activity

**Target Signal:** BULLISH (Raises: 2, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-05 | Guggenheim | $227 | $206 | +10% |
| 2025-12-02 | Barclays | $197 | $176 | +12% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-05 | Guggenheim | main | Buy |
| 2025-12-02 | Barclays | main | Equal-Weight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 1 ($0.26M) |
| Sells | 7 ($4.07M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 36.8% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 4 / 5 |

**Top Holders:**
- Vanguard Group Inc: 9.8% (-0.2%)
- Blackrock Inc.: 8.6% (+1.7%)
- State Street Corpora: 5.5% (-0.4%)
- JPMORGAN CHASE & CO: 4.9% (+109.0%)
- Geode Capital Manage: 2.3% (-7.2%)

### Key Risks

1. Insider selling cluster: $4.1M in recent transactions.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 1.07 suggests fair value with growth premium. Forward P/E 17.4x stretched relative to 6% growth. Quality metrics strong (ROE 34%, margin 27%). Balance sheet: $8.4B free cash flow. Analyst sentiment positive (2 raises, avg +11%). Insider selling cluster ($4.1M in 90 days), potential headwind. Institutional flow bullish (4 buying vs 5 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $481.8B |
| Beta | 0.35 |
| 52W Range | $140.68 - $207.81 |
| Short Interest | 0.8% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.07 |
| Forward P/E | 17.4 |
| Current P/E | 18.4 |
| YoY Growth | 6.0% |
| EPS Direction | STABLE |

### Technicals

MRS_10 deteriorating from -1.9% to -2.9% (-1.0% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 5.9pp (needs >3.0% for momentum thesis). Long-term uptrend intact (above SMA200 at 1.17x) but short-term weakness (below SMA20). MACD histogram bearish (-0.91), momentum weakening. RSI neutral at 52.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | -2.90% (CS: 26) | Weak |
| RSI_14 | 52.4 | Neutral |
| MACD Histogram | -0.91 | Bearish |
| vs SMA20 | 0.990x | Below |
| vs SMA50 | 1.029x | Above |
| vs SMA200 | 1.172x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $199.96
- **Stop Loss:** $193.90 (3.0% risk)
- **Target:** $206.02 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 49
- **Position Value:** $9,798.04
- **Portfolio %:** 9.80%
- **Risk Dollars:** $300.00
- **Risk Per Trade:** 0.30%
- **Modifiers:** L1 100% | L2 25% | Combined 0.30x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | TOXIC (Zone G) | 0.25x |

*NORMAL regime with moderate risk appetite. VIX remains in the mid-range, breadth is moderate, and yield curve is flat but not inverted—indicating standard late-cycle conditions. Upbeat earnings and positive tech momentum are offset by cautious guidance in consumer sectors, suggesting selective positioning is favored.*

### Earnings

**Next:** 2026-01-21 (Est: $2.53)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $2.76 | $2.80 | +1.5% |
| 2025Q2 | $2.68 | $2.77 | +3.2% |
| 2025Q1 | $2.58 | $2.77 | +7.4% |
| 2024Q4 | $2.01 | $2.04 | +1.4% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_10*